CA24138 - EU-Resolution Biology Network (EU-RESOLVE)

In 2021, governmental healthcare costs in the EU totaled €1,179 billion, accounting for 8.1% of GDP. Despite significant advances in understanding the mechanisms driving inflammatory diseases and the development of new therapeutics, the socio-economic burden of these conditions within the EU remains disproportionately high. This underscores the urgent need for more effective therapies to treat acute and chronic inflammatory conditions.

In the recent years, there has been a paradigm shift in our understanding of how inflammation resolves, with the discovery that its resolution is an actively regulated biochemical and cellular process. While our knowledge of these processes has expanded considerably, significant gaps remain in understanding the mechanisms that govern the resolution of inflammation. Bridging these gaps would not only enhance our understanding of fundamental biological processes but also offer insights into disease mechanisms and open new opportunities for treating inflammatory conditions by targeting the resolution pathways.

EU-RESOLVE aims to create a multidisciplinary, pan-European network of excellence in Resolution Biology. This network will bring together academics, clinicians, biotechnology companies, and other stakeholders. EU-RESOLVE will advance the understanding of the mechanisms that regulate the resolution of inflammation and accelerate the translation of these findings into more effective treatments for patients with inflammatory diseases.

EU-RESOLVE will achieve this by:

1. Consolidating fragmented expertise to foster synergy through the sharing of state-of-the-art knowledge and innovative techniques.
2. Providing cutting-edge and innovative training to build research and clinical capacity.
3. Establishing an open-access, integrated database to serve as an educational resource for the research and clinical communities.